AMAG Pharmaceuticals, Inc. to Present at
Canaccord Genuity 30th Annual Global Growth
August 03, 2010 04:08 PM Eastern Daylight Time
LEXINGTON, Mass.--(EON: Enhanced Online News)--AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG)
today announced that management will present an overview of the company at the Canaccord Genuity 30th Annual
Global Growth Conference on August 10, 2010 at 9:00 a.m. ET. The conference is being held August 10-12, 2010
in Boston, MA.
A live webcast of the presentation will be accessible through the Investors section of the company’s website at
www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals,
Inc. website for approximately two weeks.
About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the
development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel
imaging agents to aid in the diagnosis of cancer and cardiovascular disease. AMAG manufactures and sells two
commercial products, Feraheme® (ferumoxytol) Injection for intravenous (IV) use and GastroMARK®, an oral
contrast agent used in magnetic resonance imaging. For additional company information, please visit
Feraheme is a registered trademark of AMAG Pharmaceuticals, Inc.
Carol Miceli, 617-498-3361